FBXO3 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 4.43890000312308E-08 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
3.380900E-04 |
Normal-vs-Stage2 |
3.417300E-03 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
9.319200E-03 |
Stage1-vs-Stage2 |
8.340400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
9.538200E-01 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
7.858200E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.14920000018992E-07 |
Normal-vs-AfricanAmerican |
1.971360E-01 |
Normal-vs-Asian |
2.173399999994E-05 |
Caucasian-vs-AfricanAmerican |
1.276470E-03 |
Caucasian-vs-Asian |
8.927600E-01 |
AfricanAmerican-vs-Asian |
6.134500E-02 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
2.003900E-03 |
Normal-vs-Female |
1.22280000003361E-06 |
Male-vs-Female |
3.060600E-03 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
6.922600E-03 |
Normal-vs-Extreme_Weight |
3.66940000000593E-05 |
Normal-vs-Obese |
9.166100E-02 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
3.879600E-01 |
Normal_Weight-vs-Obese |
8.261200E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
7.768800E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
5.31890000043944E-07 |
Normal-vs-Age(41-60Yrs) |
5.842800E-03 |
Normal-vs-Age(61-80Yrs) |
2.4962999999989E-05 |
Normal-vs-Age(81-100Yrs) |
8.141100E-03 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.281400E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.709000E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.280100E-02 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.458400E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.906400E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.368000E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
2.691800E-01 |
Normal-vs-Grade 3 |
2.550400E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
2.666000E-01 |
Grade 2-vs-Grade 4 |
2.691800E-01 |
Grade 3-vs-Grade 4 |
2.550400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.97402999999596E-05 |
Normal-vs-N1 |
1.873970E-02 |
N0-vs-N1 |
5.835800E-01 |
|
|